Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.15887 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Friederike Holze und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Base…. Hauptthemen laut MEDLINE: Lysergic Acid Diethylamide, Hallucinogens. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Universitätsspital Basel.
Abstract (Originalsprache)
Aims
Lysergic acid diethylamide (LSD) is currently investigated for several neurological and psychiatric illnesses. Various studies have investigated the pharmacokinetics and the pharmacokinetic–pharmacodynamic relationship of LSD in healthy participants, but data on urinary recovery and confirmatory studies are missing.
Methods
The present study characterized the pharmacokinetics, pharmacokinetic–pharmacodynamic relationship and urinary recovery of LSD at doses of 85 and 170 μg administered orally in 28 healthy participants. The plasma concentrations and subjective effects of LSD were continuously evaluated over a period of 24 h. Urine was collected during 3 time intervals (0–8, 8–16 and 16–24 h after LSD administration). Pharmacokinetic parameters were determined using compartmental modelling. Concentration–subjective effect relationships were described using pharmacokinetic–pharmacodynamic modelling.
Results
Mean (95% confidence interval) maximal LSD concentrations were 1.8 ng/mL (1.6–2.0) and 3.4 ng/mL (3.0–3.8) after the administration of 85 and 170 μg LSD, respectively. Maximal concentrations were achieved on average after 1.7 h. Elimination half‐lives were 3.7 h (3.4–4.1) and 4.0 h (3.6–4.4), for 85 and 170 μg LSD, respectively. Only 1% of the administered dose was recovered from urine unchanged within the first 24 h, 16% was eliminated as 2‐oxo‐3‐hydroxy‐LSD. Urinary recovery was dose proportional. Mean (±standard deviation) durations of subjective effects were 9.3 ± 3.2 and 11 ± 3.7 h, and maximal effects ( any drug effects ) were 77 ± 18% and 87 ± 13% after 85 and 170 μg of LSD, respectively.
Conclusion
The present novel study validates previous findings. LSD exhibited dose‐proportional pharmacokinetics and first‐order elimination kinetics and dose‐dependent duration and intensity of subjective effects. LSD is extensively metabolized and shows dose‐proportional urinary recovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
- Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
ORCID-Profile: Friederike Holze, Urs Duthaler, Matthias E Liechti
Förderung
- Swiss National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Universitätsspital Basel
Zitieren
APA
Holze, F., Erne, L., Duthaler, U., & Liechti, M. E. (2024). Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15887
Vancouver
Holze F, Erne L, Duthaler U, Liechti ME. Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15887
BibTeX
@article{Holze2024,
author = {Holze, Friederike and Erne, Livio and Duthaler, Urs and Liechti, Matthias E},
title = {Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.15887}
}
EUVIMED